Regeneron and Sanofi Withdraw sBLA for Checkpoint Inhibitor Libtayo for Cervical Cancer

By PacConAdmin | January 28, 2022

Regeneron Pharmaceuticals and Sanofi are pulling their supplemental Biologics License Application (sBLA) for the indication of cervical cancer for their human monoclonal antibody, Libtayo (cemiplimab-rwlc).
Source: Drug Industry Daily

Posted in Drug Industry Daily